Swedish Orphan Biovitrum AB (publ) (OTCMKTS: BIOVF) Receives Average Analyst Rating of “Hold”
Swedish Orphan Biovitrum AB (publ) (OTCMKTS: BIOVF – Get a rating) received a consensus recommendation of “Hold” from the six analysts who cover the company, market beat reports. One research analyst has assigned the stock a sell rating, one has assigned a hold rating and three have assigned the company a buy rating. The 12-month average target price among analysts who updated their coverage of the stock in the past year is $215.00.
Several research firms have recently weighed in on BIOVF. DNB Markets upgraded Swedish Orphan Biovitrum AB (publ) shares from a “hold” rating to a “buy” rating in a Thursday, April 14 research note. Zacks Investment Research cut Swedish Orphan Biovitrum AB (publ) shares from a “hold” rating to a “sell” rating in a Wednesday, May 4 research note. Nordea Equity Research upgraded shares of Swedish Orphan Biovitrum AB (publ) from a “hold” rating to a “buy” rating in a Friday, February 11 report. Finally, Barclays raised its price target on Swedish Orphan Biovitrum AB (publ) shares from SEK 210 to SEK 215 in a report on Tuesday, February 22.
Swedish action Orphan Biovitrum AB (publ) open at $20.00 on Fridays. The company has a 50-day simple moving average of $22.05 and a 200-day simple moving average of $21.90. Swedish Orphan Biovitrum AB has a 1 year minimum of $16.05 and a 1 year maximum of $28.88. The company has a debt ratio of 0.43, a current ratio of 0.93 and a quick ratio of 0.53. The stock has a market capitalization of $6.00 billion, a price/earnings ratio of 17.24 and a beta of 0.48.
Swedish company profile Orphan Biovitrum AB (publ) (Get a rating)
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures and sells pharmaceutical products in the therapeutic areas of hematology, immunology and genetic and metabolic diseases in Europe, North America and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis (HLH); Kineret for cryopyrin-associated periodic syndrome, rheumatoid arthritis and Still’s disease; Orfadin to treat hereditary tyrosinemia type 1; and Synagis for severe lower respiratory tract infections.
Get news and reviews for Swedish Orphan Biovitrum AB (publ) Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com’s free daily email newsletter.